Studying on the progress of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors

Xinyi Yang, Reshetov I.V., Poltavskaya M.G., Agakina Yu.S., Kulikov T.S.

University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Cardiotoxicity (CT) is a serious side effect of anticancer drugs, especially death receptor 1 (PD-1) or death ligand 1 (PD-L1). Immune checkpoint inhibitors (ICIs) have attracted wide attention in recent years. This article describes the progress in studying CT induced by PD-1 and PD-1/PD-L1 ICIs. An overview of PD-1 and PD-1/PD-L1 immune checkpoint inhibitors, their CT manifestations, potential mechanisms, diagnostic and therapeutic methods are presented.

Keywords

About the Authors

Corresponding author: Yang Xinyi, PhD student, Department of Oncology, Reconstructive Surgery and Radiology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; xinyiyang@yandex.ru; ORCID: https://orcid.org/0009-0009-2320-0834

Similar Articles